Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 369


What is the optimal anticoagulation in patients with a left ventricular assist device?

Rossi M, Serraino GF, Jiritano F, Renzulli A.

Interact Cardiovasc Thorac Surg. 2012 Oct;15(4):733-40. Epub 2012 Jul 3. Review.


Antithrombotic therapy for left ventricular assist devices in adults: a systematic review.

Baumann Kreuziger LM, Kim B, Wieselthaler GM.

J Thromb Haemost. 2015 Jun;13(6):946-55. doi: 10.1111/jth.12948. Epub 2015 May 9. Review.


What do you do with the antiplatelet agents in patients with drug eluting stents who then receive a mechanical valve?

Rossi M, Serraino GF, Spadafora A, Renzulli A.

Interact Cardiovasc Thorac Surg. 2012 Jul;15(1):115-21. doi: 10.1093/icvts/ivs104. Epub 2012 Mar 28. Review.


How does successful bridging with ventricular assist device affect cardiac transplantation outcome?

Urban M, Pirk J, Dorazilova Z, Netuka I.

Interact Cardiovasc Thorac Surg. 2011 Oct;13(4):405-9. doi: 10.1510/icvts.2011.273722. Epub 2011 Jul 25. Review.


Low thromboembolic risk for patients with the Heartmate II left ventricular assist device.

John R, Kamdar F, Liao K, Colvin-Adams M, Miller L, Joyce L, Boyle A.

J Thorac Cardiovasc Surg. 2008 Nov;136(5):1318-23. doi: 10.1016/j.jtcvs.2007.12.077. Epub 2008 Sep 14.


Increased incidence of gastrointestinal bleeding following implantation of the HeartMate II LVAD.

Stern DR, Kazam J, Edwards P, Maybaum S, Bello RA, D'Alessandro DA, Goldstein DJ.

J Card Surg. 2010 May;25(3):352-6. doi: 10.1111/j.1540-8191.2010.01025.x. Epub 2010 Mar 10.


Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device.

Stulak JM, Lee D, Haft JW, Romano MA, Cowger JA, Park SJ, Aaronson KD, Pagani FD.

J Heart Lung Transplant. 2014 Jan;33(1):60-4. doi: 10.1016/j.healun.2013.07.020. Epub 2013 Sep 7.


Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy.

John R, Kamdar F, Liao K, Colvin-Adams M, Boyle A, Joyce L.

Ann Thorac Surg. 2008 Oct;86(4):1227-34; discussion 1234-5. doi: 10.1016/j.athoracsur.2008.06.030.


Can the temporary use of right ventricular assist devices bridge patients with acute right ventricular failure after cardiac surgery to recovery?

Lang SA, O'Neill B, Waterworth P, Bilal H.

Interact Cardiovasc Thorac Surg. 2014 Apr;18(4):499-510. doi: 10.1093/icvts/ivt472. Epub 2013 Dec 25. Review.


Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy.

Slaughter MS, Naka Y, John R, Boyle A, Conte JV, Russell SD, Aaronson KD, Sundareswaran KS, Farrar DJ, Pagani FD.

J Heart Lung Transplant. 2010 Jun;29(6):616-24. doi: 10.1016/j.healun.2010.02.003. Epub 2010 Apr 18.


Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation.

Sandner SE, Riebandt J, Haberl T, Mahr S, Rajek A, Schima H, Wieselthaler GM, Laufer G, Zimpfer D.

J Heart Lung Transplant. 2014 Jan;33(1):88-93. doi: 10.1016/j.healun.2013.10.009. Epub 2013 Oct 11.


Platelet activation in heart failure patients supported by the HeartMate II ventricular assist device.

Slaughter MS, Sobieski MA 2nd, Graham JD, Pappas PS, Tatooles AJ, Koenig SC.

Int J Artif Organs. 2011 Jun;34(6):461-8. doi: 10.5301/IJAO.2011.8459.


Thrombolysis for suspected intrapump thrombosis in patients with continuous flow centrifugal left ventricular assist device.

Muthiah K, Robson D, Macdonald PS, Keogh AM, Kotlyar E, Granger E, Dhital K, Spratt P, Jansz P, Hayward CS.

Artif Organs. 2013 Mar;37(3):313-8. doi: 10.1111/j.1525-1594.2012.01567.x. Epub 2013 Feb 4.


Safety and effectiveness of low dosing of double antiplatelet therapy during long-term left ventricular support with the INCOR system.

Attisani M, Centofanti P, La Torre M, Campanella A, Sansone F, Rinaldi M.

J Artif Organs. 2010 Dec;13(4):202-6. doi: 10.1007/s10047-010-0527-7. Epub 2010 Dec 4.


Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients.

Boyle AJ, Jorde UP, Sun B, Park SJ, Milano CA, Frazier OH, Sundareswaran KS, Farrar DJ, Russell SD; HeartMate II Clinical Investigators.

J Am Coll Cardiol. 2014 Mar 11;63(9):880-8. doi: 10.1016/j.jacc.2013.08.1656. Epub 2013 Dec 11.


Assessment of platelet function with light transmission aggregometry in 24 patients supported with a continuous-flow left ventricular assist device: a single-center experience.

Fiore M, James C, Mouton C, Calderon J, Barandon L, Ouattara A, Picard F.

J Thorac Cardiovasc Surg. 2014 Dec;148(6):3119-25.e1. doi: 10.1016/j.jtcvs.2014.07.091. Epub 2014 Aug 6.


Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables.

John R, Pagani FD, Naka Y, Boyle A, Conte JV, Russell SD, Klodell CT, Milano CA, Rogers J, Farrar DJ, Frazier OH.

J Thorac Cardiovasc Surg. 2010 Jul;140(1):174-81. doi: 10.1016/j.jtcvs.2010.03.037. Epub 2010 May 5.


Antiplatelet Therapy and Adverse Hematologic Events During Heart Mate II Support.

Saeed O, Shah A, Kargoli F, Madan S, Levin AP, Patel SR, Jermyn R, Guerrero C, Nguyen J, Sims DB, Shin J, D'Alessandro D, Goldstein DJ, Jorde UP.

Circ Heart Fail. 2016 Jan;9(1):e002296. doi: 10.1161/CIRCHEARTFAILURE.115.002296.


The use of eptifibatide for suspected pump thrombus or thrombosis in patients with left ventricular assist devices.

Tellor BR, Smith JR, Prasad SM, Joseph SM, Silvestry SC.

J Heart Lung Transplant. 2014 Jan;33(1):94-101. doi: 10.1016/j.healun.2013.11.002. Epub 2013 Nov 25.

Items per page

Supplemental Content

Write to the Help Desk